Exelixis Gains 15.6% YTD: How Should You Play the Stock?

Exelixis (EXEL) shares have significantly outperformed year-to-date, gaining 15.6%, driven by strong demand for its lead drug Cabometyx, including a recent label expansion for neuroendocrine tumors, and positive top-line results from the STELLAR-303 study for pipeline candidate zanzalintinib in colorectal cancer. However, the company reported a Q2 revenue miss and faces increasing competition for Cabometyx in renal cell carcinoma. Despite encouraging broader pipeline progress, EXEL's valuation remains elevated at 4.14x forward sales, suggesting a cautious near-term outlook for new investors.

Analysis

Exelixis (EXEL) presents a dual narrative of strong clinical progress balanced by commercial pressures and a high valuation. The stock's 15.6% year-to-date gain, outperforming the industry's 2.9% growth, is underpinned by the solid performance of its lead drug, Cabometyx, which remains the leading tyrosine kinase inhibitor (TKI) for renal cell carcinoma (RCC). Growth is further supported by a recent label expansion into neuroendocrine tumors (NET), which already constituted over 4% of Cabometyx demand in the second quarter. A significant catalyst has been the positive top-line data from the STELLAR-303 study for its next-generation TKI, zanzalintinib, which demonstrated a statistically significant improvement in overall survival in metastatic colorectal cancer, thereby increasing its probability of regulatory success. However, these positive developments are tempered by a recent second-quarter revenue miss that caused a stock pullback, stiff competition in the RCC market from major players like Merck's Keytruda, and a strategic discontinuation of a Phase 3 trial for zanzalintinib in another indication. The company's valuation is a key concern, with shares trading at 4.14x forward sales—a premium to both its historical mean and the industry average—suggesting that strong execution is already priced in and leaving little room for error.

Key Decisions for Investors

• Existing investors could consider holding positions to capitalize on the continued sales growth from Cabometyx's new NET indication and the de-risked potential of the zanzalintinib pipeline following positive Phase 3 data.
• Prospective investors should exercise caution, as the stock's premium valuation at 4.14x forward sales, combined with a recent Q2 revenue miss, may warrant waiting for a more favorable entry point or further evidence of sustained growth.
• Monitor competitive dynamics in the RCC market, particularly market share shifts relative to Merck's Keytruda, and track progress on zanzalintinib's final trial analysis and regulatory filings, as these are the primary determinants of EXEL's future value.